APA

Goldwirt L., Chami I., Feugeas J., Pages C., Brunet-Possenti F., Allayous C., Baroudjian B., Madelaine I., Sauvageon H., Mourah S. & Lebbé C. (20160520). Reply to 'Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance' by Funck-Brentano et al. : Annals of oncology : official journal of the European Society for Medical Oncology.

Chicago

Goldwirt L, Chami I, Feugeas J-P, Pages C, Brunet-Possenti F, Allayous C, Baroudjian B, Madelaine I, Sauvageon H, Mourah S and Lebbé C. 20160520. Reply to 'Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance' by Funck-Brentano et al. : Annals of oncology : official journal of the European Society for Medical Oncology.

Harvard

Goldwirt L., Chami I., Feugeas J., Pages C., Brunet-Possenti F., Allayous C., Baroudjian B., Madelaine I., Sauvageon H., Mourah S. and Lebbé C. (20160520). Reply to 'Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance' by Funck-Brentano et al. : Annals of oncology : official journal of the European Society for Medical Oncology.

MLA

Goldwirt L, Chami I, Feugeas J-P, Pages C, Brunet-Possenti F, Allayous C, Baroudjian B, Madelaine I, Sauvageon H, Mourah S and Lebbé C. Reply to 'Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance' by Funck-Brentano et al. : Annals of oncology : official journal of the European Society for Medical Oncology. 20160520.